Keymed Biosciences Announces Interim Results for First Half of 2024

CHENGDU, China, Aug. 28, 2024 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced its interim results for the first half of 2024, along with a corporate update. 

Rapid development of our pipeline products

Stapokibart (CM310) (IL-4Rα antibody)

CMG901/AZD0901 (Claudin 18.2 ADC)

CM313 (CD38 antibody)

⁹⁹

CM326 (TSLP antibody)

CM355/ICP-B02 (CD20xCD3 bispecific antibody)

CM336 (BCMAxCD3 bispecific antibody)

CM350 (GPC3xCD3 bispecific antibody)

CM369/ICP-B05 (CCR8 antibody)

CM383 (Aβ protofibrils antibody)

CM380 (GPRC5DxCD3 bispecific antibody)

Financial and Business Highlights

View original content:https://www.prnewswire.co.uk/news-releases/keymed-biosciences-announces-interim-results-for-first-half-of-2024-302232637.html